Groupe d'Etude en Oncologie du Quebec

Titre	A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases
Protocole ID	EBV-TCL-01
ClinicalTrials.gov ID	NCT02580539
Type(s) de cancer	Lymphome non-hodgkinien (LNH)
Phase	Phase I-II
Type étude	Traitement
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur(trice) principal(e)	Dr Jean-Sébastien Delisle
Coordonnateur(trice)	Stéphanie Thiant 514-252-3400 poste 4681
Statut	Fermé
Critètes d'éligibilité	Capacity to provide informed consent Age ≥ 18 years old Confirmed treatment-refractory EBV reactivation or EBV-related lymphoma ECOG of 2 or less DONOR ELIGIBILITY: An allogeneic donor must be a first-degree relative with at least 3/6 HLA compatibility, have consented to donate peripheral blood mononuclear cells, and fulfill the same criteria for stem cell donation according to the hospital's standard operating procedure.
Critètes d'exclusion	Medical condition requiring a corticosteroid dose greater than Prednisone 0.5mg/kg/day (or equivalent) at the time of the infusion. Patient has received T-cell depleting antibodies or stem cell transplantation in the 28 days prior to proposed date of anti-EBV T-cell line infusion Patient has received a solid organ transplant in the 3 months prior to proposed date of anti-EBV T-cell line infusion. Pregnant or nursing females Life expectancy of less than 3 months due to a condition unrelated to the EBV- related disease. Active uncontrolled GVHD Active uncontrolled SOT rejection episode

Groupe d'étude en oncologie du Québec